A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
about
Therapeutic options in peripheral T cell lymphomaRomidepsin for the Treatment of Peripheral T-Cell LymphomaPruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative ReviewMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyHighly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic ReviewRomidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataBelinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Novel therapeutic agents for cutaneous T-Cell lymphoma.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assayBelinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.HDAC inhibitor-based therapies: can we interpret the code?Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Ibrutinib in B lymphoid malignancies.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Targeting histone deacetylases in T-cell lymphoma.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaDifferential Regulation of Telomerase Reverse Transcriptase Promoter Activation and Protein Degradation by Histone Deacetylase Inhibition.Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.Recent advances in understanding and managing T-cell lymphoma.Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphomaHistone Deacetylase Inhibitors and Diabetic Kidney DiseaseHistone deacetylase 6 in cancerNext-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation
P2860
Q26748857-7E704CC2-0F41-41F1-8864-A9DC9C51675EQ26785732-D3DB2C12-D6F0-4DAD-8C87-C63E3633BE76Q28075343-0664E9D8-225F-44FF-B165-84BE6FA9DB9AQ28075606-ABF0F287-52CC-412E-835E-5C4C4D614A8DQ28082536-5E0E35E5-BE22-42E5-AD8E-57A22BC737AAQ28554530-B10C76E0-F41D-4CC5-BB5D-0A6216FADC21Q30936712-076DE778-9097-4088-B6B6-17AAD7502212Q33423816-119F0797-0331-4854-BDDE-27E293E88CA7Q33436867-C133AEB4-E5DB-41CF-9055-DC9E9CAD69B2Q34307446-F24FABA7-610C-4F8E-A23E-57F0B5954082Q34516083-3F424E4F-9C3B-4E85-9377-40ED4A5B50AFQ35703714-645C684B-E5F1-480B-967B-85098202FBF7Q35859219-B337C46D-302A-47D6-BECD-BFD618B4B898Q36161365-EB010CA7-41A8-41A9-BBDE-BFC94188C10FQ36470196-89E2E592-EFE6-435B-A8F9-02CD07DAA9F1Q37271019-A6E78545-BCA8-477A-9091-BEEB027AFD00Q37355651-F8500FCC-53AE-4B80-BD62-A21C73852526Q37578338-5194B26E-76A6-43D2-BFC7-34BFA7330A7CQ37579991-78CD6E81-6D83-4CF9-AC82-B5AD60501FA5Q38058971-4E597037-6BAA-4A52-8F03-AE99E4C6D41CQ38515832-BB72AC0A-81E5-413E-900F-080C6074B752Q38545545-8550A8E2-B4BB-4244-A3AB-1337D1D684BFQ38595978-10BDF103-A95D-4B8F-9C4A-D42D987FFC45Q38752460-E077CD94-389F-43BF-8F6F-7A699CD71C4BQ38765451-F4459CCA-FBF7-4166-AEB0-AD982ADD5837Q38998630-B9352F59-B8B5-4647-97AB-9507262D2F12Q39062353-1DAC29AB-AE6C-4CFB-B25B-9472E73102C0Q39091822-7E07C2D7-DC5D-4363-9858-553BCB7166E5Q39287526-785A3C36-DABC-429F-B10B-310817D658DDQ39955238-0DEBA398-0116-40B0-8681-65B9F4548989Q40388317-2138F2EC-5219-47E7-B78B-C1775E331DC5Q42784091-31CD12E2-9F2D-4CD5-91C9-E4730E52674CQ47131247-E3BBE554-170F-4DA1-A16E-F2A18FAC86DFQ48197102-BFB0C02C-0906-44EF-ABB0-5B5D8015CB6EQ50853522-DB7B268B-9056-4D9F-8255-39D903270479Q55334211-10E68033-B313-49D3-BD9C-C1BF18D2C96BQ58705889-52C91BFD-EB49-4998-8C5B-B7BBB502E5B4Q58762435-9FB9DDFC-3D1D-48D7-ADA3-FBF68239848AQ58768571-C66DDD86-AFD9-4A45-BA3E-1EDABFCA5FA5Q58798742-EF709501-FD21-4572-881F-DD95CC4133CA
P2860
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@ast
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@en
type
label
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@ast
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@en
prefLabel
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@ast
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@en
P2093
P2860
P356
P1476
A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.
@en
P2093
Arnuparp Lekhakula
Brad Pohlman
Dina Ben-Yehuda
Eric D Jacobsen
Francine Foss
Gajanan Bhat
Guy Laurent
Kenneth B Hymes
Lee F Allen
Madeleine Duvic
P2860
P304
P356
10.1111/BJH.13222
P407
P577
2014-11-17T00:00:00Z